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Abstract The optimal management of patients with low-
grade glioma (LGG) is controversial. The controversy
largely stems from the lack of well-designed clinical trials
with adequate follow-up to account for the relatively long
progression-free survival and overall survival of patients
with LGG. Nonetheless, the literature increasingly suggests
that expectant management is no longer optimal. Rather,
there is mounting evidence supporting active management
including consideration of surgical resection, radiotherapy,
chemotherapy, molecular and histopathologic characteriza-
tion, and use of modern imaging techniques for monitoring
and prognostication. In particular, there is growing evidence
favoringextensive surgical resectionandincreasinginterestin
the role of chemotherapy (especially temozolomide) in the
management of these tumors. In this review, we critically
analyze emerging trends in the literature with respect to
management of LGG, with particular emphasis on reports
published during the past year.
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Introduction
Despite their initially indolent nature, low-grade gliomas
(LGGs) may cause considerable morbidity and inevitably
lead to death. Whereas expectant management once was
acceptable and the norm, current trends and mounting
evidence now favor more active management, including
consideration of surgical resection, radiotherapy, chemo-
therapy, molecular and histopathologic characterization,
and use of modern imaging techniques for monitoring and
prognostication. Some of these changes have gained
significant momentum and support, whereas others remain
investigational and controversial. In this review, we
critically analyze emerging trends in the literature with
respect to management of LGGs, with particular emphasis
on reports published during the past year.
Definition and Epidemiology
The term LGG technically includes all World Health
Organization (WHO) grade I and II gliomas. However, this
broad grouping contains tumors that are clinically, histo-
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management of WHO grade I gliomas is dramatically
different from that of WHO grade II gliomas, the former
being amenable to surgical cure while the role of surgery
for the latter is still being justified. Therefore, in the context
of this review, LGG refers only to WHO grade II diffuse
astrocytomas, oligodendrogliomas, and oligoastrocytomas,
all of which have similar invasive and malignant potential.
Approximately 2,000 to 3,000 LGGs are diagnosed in the
United States every year, accounting for nearly 15% of all
primary brain tumors. Peak incidence occurs in people
between 35 and 44 years of age, and there is an increased
prevalence among white people and men [1]. Despite a
preponderance of astrocytomas, there has been an increas-
ing diagnosis and/or incidence of pure oligodendrogliomas
and mixed oligoastrocytomas in recent years [2]. Low-
grade astrocytomas have a predilection for “secondary”
functional areas, such as the supplementary motor area and
the insular lobe, whereas oligodendrogliomas are seen most
commonly along the convexity in subcortical areas,
particularly in the frontal lobe [3].
The patient’s presenting symptoms and imaging character-
istics are critical guides for management. Seizure is the most
common presenting symptom, occurring in up to 80% of
patients [4]. Other less common modes of presentation
include headache, lethargy, and personality changes. In still
others, the slow-growing nature of the tumor may conceal
the diagnosis for years. When patients present with symp-
toms related to mass effect or intracranial hypertension,
surgical treatment often is necessary and undisputed. In
contrast, patients who do not have evidence of radiographic
tumor growth and whose symptoms are well controlled
medically are the ones in whom management becomes
difficult and controversial. This controversy largely stems
from the lack of well-designed clinical trials with adequate
follow-up to account for the relatively long progression-free
survival (PFS, 36–95 months) and overall survival (OS,
≥7 years) some patients with LGG enjoy [4–6, 7•]
Prognostic Factors
The most important negative prognostic factors to emerge
from the literature include increasing age, astrocytic
histology, large tumor diameter (>4–6 cm), tumors crossing
the midline, neurologic deficits, and poor performance
status [2, 4–6, 7•, 8, 9]. In contrast, presentation with
seizures, which generally occur in patients who are
otherwise neurologically intact, often is identified as a
positive prognostic factor [5, 8, 9]. (Schiff et al. [9] provide
a more extensive review of prognostic factors for LGG.) In
2002, Pignatti et al. [4] described a simple scoring system
to account for these important prognostic factors so that
physicians could better counsel patients and stratify patients
for subsequent trials (Table 1). Based on a multivariate
analysis of data from one prospective European Organisa-
tion for Research and Treatment of Cancer (EORTC) trial
and validated on the data from another, they assigned one
point each for age ≥40 years, astrocytoma histology,
maximal tumor diameter ≥6 cm, tumor crossing the
midline, and presence of neurologic deficit before surgery.
Low-risk patients (scores 0–2) had a median OS of
7.72 years, compared with 3.20 years for high-risk patients
(scores 3–5) [4]. The University of California, San
Francisco (UCSF) group recently introduced a new LGG
scoring system that uses a four-point scoring system to
predict OS and PFS, assigning one point each for age
greater than 50 years, Karnofsky performance score (KPS)
≤80, maximum tumor diameter greater than 4 cm, and
eloquent involvement of the tumor (Table 1)[ 7•]. When
stratified according to low-risk (scores 0–1), medium-risk
(score 2), and high-risk (scores 3–4) groups, 5-year OS was
97%, 81%, and 56%, respectively, and 5-year PFS was
76%, 49%, and 18%, respectively [7•]. This newer scoring
system is unique in that it is the first such system to
consider eloquence as a poor independent prognostic factor.
The importance of eloquence may be attributable to being
at higher risk of neurologic deficits but also may speak to
the resectability of a tumor, as patients with noneloquent
tumors are more likely to have more extensive resections.
The impact of increasing age on the LGG prognosis has
received particular attention during the past year because
older patients (ie, those ≥55–60 years of age) are
increasingly being diagnosed with LGG. As might be
expected, older patients with LGG have a poorer prognosis,
Table 1 Low-grade glioma scoring systems
Criterion Points (yes/no), n/n
2008 LGG scoring system (UCSF) [7•]
a
Age >50 y 1/0
KPS ≤80 1/0
Eloquent location (presumed) 1/0
Maximum diameter >4 cm 1/0
2002 LGG scoring system (Pignatti et al.) [4]
b
Age ≥40 y 1/0
Astrocytoma histology 1/0
Maximum diameter ≥6 cm 1/0
Tumor crossing midline 1/0
Neurologic deficit 1/0
KPS Karnofsky performance score, LGG low-grade glioma, UCSF
University of California, San Francisco
aRisk stratification: low = 0–1 points, medium = 2 points, high = 3–4
points
bRisk stratification: low = 0–2 points, high = 3–5 points
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additional year of age has a negative impact on prognosis,
suggesting that reports from investigators studying age as a
binomial likely have understated the impact of increasing
age on outcomes [10, 11]. Despite the poorer prognosis,
however, patients who survive 2 years beyond the initial
diagnosis may experience prolonged PFS [10].
Imaging
Besides the prognostic factors already reviewed, there is
increasing interest in the role of imaging in the management
of LGG. Several studies have been published touting the
prognostic significance of various imaging findings, in-
cluding contrast enhancement, tumor growth rates, choline
and creatinine peaks on magnetic resonance (MR) spec-
troscopy, relative cerebral blood volume (rCBV), and
absolute diffusion coefficients (ADCs) [12–15]. Unfortu-
nately, studies directly comparing these various MRI-based
imaging modalities are limited. In one comparative study,
MR spectroscopy was shown to be superior to tumor
growth rates and rCBV measurements for predicting
anaplastic transformation [15]. On the other hand, in
another study, tumor growth rate was superior to initial
volume, rCBV, and ADC for predicting PFS and OS [14].
The relative importance of imaging findings compared
with known prognostic factors is difficult to ascertain because
studies rarely simultaneously account for known prognostic
factors and imaging findings. The study by Chaichana et al.
[16] of the prognostic significance of contrast enhancement
is an exemplary exception. Before concluding that contrast
enhancement portends decreased survival and increased
recurrence, the authors demonstrated that the two groups
studied (those with and without contrast enhancement) were
well matched with respect to all known prognostic factors
(eg, KPS and age) [16]. Further prospective studies
incorporating clinically important prognostic factors and
imaging findings will need to be conducted to understand
the true importance of these novel imaging modalities.
Molecular Pathogenesis
Further advances in the management of LGG will be made
only by developing a more thorough understanding of the
pathogenesis of these tumors. Recent reports have dramat-
ically altered our conceptual framework of LGG molecular
genetics, suggesting that isocitrate dehydrogenase (IDH)
mutations are an early event in LGG pathogenesis. IDH1,
found in the cytoplasm and peroxisome, catalyzes the
oxidative decarboxylation of isocitrate to α-ketoglutarate,
reducing NADP
+ to NADPH.
Previously, it was recognized that most LGGs harbored
one of two mutually exclusive genetic changes: TP53
mutations in most low-grade astrocytomas and deletions of
chromosomes 1p and 19q in most pure low-grade oligo-
dendrogliomas (Table 2)[ 9]. Low-grade mixed gliomas
tend to have either TP53 mutation or 1p/19q codeletion.
Recent studies, however, have demonstrated IDH1 muta-
tions in 59% to 90% of grade II astrocytomas, 68% to 85%
of grade II oligodendrogliomas, and 50% to 83% of grade
II oligoastrocytomas (Table 2)[ 17–19, 20•, 21]. The fact
that IDH1 mutations are seen in similar frequencies in
tumors with TP53 mutation and 1p/19q deletion suggests
these mutations may precede other genetic alterations [17,
20•]. This is supported further by serial biopsies of LGGs
showing that when IDH1 mutations occur, they always
precede and never follow TP53 mutation or loss of
heterozygosity of 1p/19q [19, 22]. Moreover, large-scale
genetic sequencing of 105 glioblastomas identified IDH1
mutations in almost all secondary glioblastomas but in only
7% of primary (de novo) glioblastomas [23].
IDH mutations in gliomas have some remarkable
features. First, every IDH1 mutation occurs in codon 132,
which normally codes for an arginine in the enzyme’s
active site. All produce amino acid substitutions, which in
more than 90% is a histidine, resulting in decreased
catalytic activity [17, 19, 20•]. IDH1 shares substantial
homology with IDH2, a mitochondrial enzyme catalyzing
the same reaction. Rare IDH2 mutations also were
recognized recently in gliomas, especially oligodendroglio-
mas [18, 20•]. All IDH2 mutations are point mutations at
codon 172 in the enzyme’s active site, a position represent-
ing the precise analogue of R132 in IDH1. IDH mutations
are exceedingly rare in pediatric gliomas, nonglioma brain
tumors, and other cancers [18].
The mechanisms by which IDH mutations predispose to
gliomagenesis remain mysterious. Although the mutated
protein is catalytically less active, consistent with a loss of
function, these mutations are always heterozygous. More-
over, none of the mutations is a nonsense mutation, further
suggesting the mutations may produce a dominant negative
or gain of function [24]. Thus, IDH1 and IDH2 seem to
function as tumor suppressor genes. Their inactivation has
been shown to induce genes crucial to angiogenesis,
although the relevance of this finding to LGGs that lack
angiogenesis remains uncertain [24].
Investigation of the role of cancer-related cell signaling
pathways continues in LGG. Recent reports highlight the
importance of the MAPK pathway in pilocytic astrocyto-
mas, with many of these tumors manifesting tandem
duplication of 7q, resulting in a fusion gene incorporating
the kinase domain of the BRAF oncogene with constitutive
BRAF activity [25]. However, the 7q34 duplication is not
seen in grade II astrocytomas [26]. Another important
226 Curr Neurol Neurosci Rep (2010) 10:224–231oncogenic signaling pathway is the PI3K-Akt-mTOR
pathway, on which PTEN normally serves as a brake.
Although PTEN sometimes is mutated in primary glioblasto-
mas, PTEN mutations do not occur in LGG. However, most
LGGs epigenetically silence PTEN via hypermethylation [27,
28]. Evidence of overactivation of the PI3K-Akt-mTOR
pathway manifesting as phosphorylation of downstream
proteins appeared to correlate inversely with survival,
although numbers were small and this finding requires
confirmation [28].
To what extent molecular markers such as 1p/19q
codeletion status, IDH mutational status, and the presence or
absence of MGMT promotor hypermethylation, which is a
prognostic factor in glioblastoma outcome, predict respon-
siveness to specific therapies or overall prognosis remains
uncertain. The presence of 1p/19q deletion seems to portend a
better prognosis in LGG, although its favorable impact is
weaker than in grade III gliomas. Small studies have
suggested that MGMT methylation status may predict
improved OS [29], but the small size of these studies and a
potential confounding correlation between MGMT methyla-
tion and 1p/19q codeletion mandate larger studies. Similarly,
in univariate analyses, IDH1 mutations conferred improved
OS in low-grade and anaplastic gliomas as well as in
glioblastomas, but it remains unclear whether mutational
status retains prognostic significance when other prognostic
markers are incorporated into multivariate models [19, 21].
Surgical Resection
ThelackofpathognomonicimagingforLGGandtheneedfor
molecular, chromosomal, and histopathologic characteriza-
tion of tumors mandate tissue acquisition for accurate
diagnosis, prognostication, and management. Needle biopsy
specimens have been associated with a greater than 50%
misdiagnosis rate [30, 31]. Surgical resection (vs biopsy
alone) affords a better opportunity to characterize, grade, and
study tumor tissue to ensure proper diagnosis, treatment, and
prognostication. Despite the lack of a randomized controlled
trial, the evidence for the benefits of extensive surgical
resection is growing. In 2001, Keles et al. [32]r e v i e w e dt h e
literature and concluded that a preponderance of the evidence
favored more extensive resection for patients with LGG.
Since then, several additional long-term institutional studies
have been published favoring extensive surgical resection [8,
33, 34, 35•]. Smith et al. [35•] retrospectively analyzed
outcomes in 216 patients who underwent surgical resection
for LGG at UCSF between 1989 and 2005, from a total of
more than 800 patients treated for LGG during that period.
Patients who underwent biopsy were specifically excluded
because such patients usually have complicating factors and
inclusion might confound the interpretation of the results. On
multivariate analysis, extent of resection (EOR) was signif-
icantly associated with improved OS but not PFS. Five-year
survival in patients with at least 90% EOR was 97%,
whereas it was 76% in those with less than 90% EOR [35•].
In 170 patients treated surgically at Johns Hopkins Hospital
between 1996 and 2007, McGirt et al. [33] similarly found
that gross total resection (GTR; based on independent
radiologist interpretation) was independently associated with
improved OS and PFS compared with subtotal resection
(5-year OS: 95% vs 70%, P=0.017; median time to
progression: 7vs3.5years,P=0.043). Although these studies
suggest GTR is desirable, not all tumors are amenable to
GTR. Predictors of incomplete tumor resection include
tumor involvement of the corticospinal tract, large tumor
volume, and oligodendroglioma histopathologic type [36].
Some may argue that enthusiasm for these retrospective
reports must be tempered by results from prospective trials
and other retrospective series that failed to find a significant
prognostic effect of EOR. For example, the prospective
intergroup American trial comparing low- and high-dose
radiation therapy found EOR to be a significant prognostic
factor for both OS and PFS on univariate analysis but found it
was not significant on multivariate analysis [2]. Similarly,
Pignatti et al. [4], who retrospectively studied the prospec-
tively collected data from EORTC trials 22844 and 22845,
found that extensive surgery (ie, >90%) was associated with
longer OS on univariate analysis but failed to show
significance on multivariate analysis. Although prospective,
these studies have significant shortcomings, including
neurosurgeon assessment of EOR, inclusion of biopsied
patients in the analyses, and the fact that the studies were not
primarily designed or powered to assess the effect of EOR.
In addition to OS and PFS, cognitive and quality-of-life
outcomes after surgical resection must be considered,
especially because concerns regarding these outcomes have
thwarted the enthusiasm for radiotherapy. Although surgery
may transiently exacerbate baseline deficits, most patients
Finding Astrocytoma, % Oligoastrocytoma, % Oligodendroglioma, %
1p/19q Codeletion
a 74 5 6 9
p53 Mutation
a 53 44 13
IDH mutation [17–19, 20•, 21]5 9 –90 50–83 68–85
MGMT hypermethylation
a 30–50 Data lacking 85
Table 2 Molecular findings in
low-grade glioma
IDH isocitrate dehydrogenase
aPlease see the review by Schiff et
al. [9] for a more comprehensive
analysis of molecular findings
and their prognostic significance
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function within 3 months [37]. Moreover, advances in
intraoperative technology (eg, neuronavigation) and pre-
and intraoperative brain mapping techniques (eg, functional
MRI, magnetic source imaging, and cortical and subcortical
stimulation mapping) now allow neurosurgeons to tailor
resections to individual functional brain architecture,
minimizing the risk of permanent deficit to less than 2%
and ensuring that patients’ quality of life is preserved [38,
39]. Duffau et al. [39] found that LGG patients operated on
with the assistance of cortical stimulation had a significantly
lowerpermanentdeficitrate,ahigherGTRrate,andasurvival
advantage compared with patients who were operated on
without intraoperativemapping.Infact, the authors foundthat
mapping may be used to identify dynamic changes in
individual patients’ functional brain architecture, allowing
more extensive tumor resections using a multistaged surgical
approach [40]. Besides making surgeries safer and more
extensive, advances in brain mapping also have made
surgery an option for more patients [39]. In particular, there
has been significantly increased interest in the surgical
management of insular gliomas, which are challenging from
an anatomic and eloquence standpoint but can be resected
with only a 6% risk of postoperative deficit [41].
Ideally, a multicenter, multinational, prospective trial
should be conducted to address this issue, but such a trial is
unlikely because of the difficulty in recruiting sufficient
numbers to demonstrate differences, the long-term follow-
up that would be necessary, and ethical concerns that
sufficient data already exist supporting GTR.
Radiotherapy
Among all available treatment modalities, radiotherapy is
the only intervention shown in a randomized controlled trial
to provide some benefit to LGG patients [42]. Even so, the
optimal role for radiotherapy in the management of patients
with LGG remains unclear. EORTC 22845 reported longer
PFS and increased rates of seizure control in patients
receiving upfront radiotherapy (54 Gy) compared with
patients who were treated at the time of progression (PFS:
5.3 vs 3.4 years, P<0.0001; seizure control rates: 75% vs
59%, P=0.0329). OS, however, was not significantly
different between the two groups (7.4 vs 7.2 years) [42].
Despite its efficacy with respect to PFS and seizure control,
the authors concluded that radiotherapy might still be
deferred in patients with LGG who are “in a good
condition.” The ambivalence is attributable, in part, to the
fact that quality of life was not studied; therefore, it was
unclear at what cost patients with LGG were realizing a
benefit in PFS and seizure control without an OS
advantage. Moreover, by delaying radiotherapy, 35% of
patients in the latter group (with a median follow-up of
7.4 years) never required radiation therapy, sparing them
the possible adverse effects of radiation [42].
Recent studies therefore focused on quality-of-life meas-
ures after radiotherapy to better define its role in managing
patients with LGG. Radiation leukoencephalopathy may
ensue months to years after radiotherapy of the brain and
may include progressive deterioration in personality, gait and
balance, urinary continence, attention,memory, and executive
function [43]. To reduce such risks, studies have been
conducted demonstrating that total dose, fractional dose,
and irradiation fields can be reduced without affecting the
efficacy of treatment (see Baumert and Stupp [44] for more
extensive reviews of this subject). Still, patients with LGG
are at substantial risk of suffering from these complications
because of their relatively long OS. Douw et al. [45]r e c e n t l y
reported the most comprehensive and long-term analysis of
cognitive and quality-of-life outcomes in 65 patients with
LGG, half of whom had received radiotherapy. With a mean
follow-up of 12 years, 27% of patients who had not been
irradiated had significant cognitive deficits in at least 5 of 18
neuropsychological test parameters, whereas 53% of patients
who received radiotherapy had significant cognitive deficits.
Deficits were most pronounced in the domains of cognitive
processing and attention, but nonsignificant differences also
were observed in information processing speed, psychomotor
functioning, and working memory [45]. These long-term
sequelae of radiotherapy further challenge its upfront and
systematic use considering radiotherapy and its complica-
tions can be delayed for more than a decade in some patients
and the fact that advances in other treatment domains (eg,
surgery and chemotherapy) may obviate the need for upfront
radiation. Do patients who have had a GTR receive any
additional benefit from radiotherapy? Likewise, does radio-
therapy confer any advantage to patients who are treated with
upfront temozolomide? As described in the “Chemotherapy”
section, trialsare currently under way toanswer these types of
questions.
Chemotherapy
With respect to chemotherapy, neuro-oncologists have
focused their attention largely on temozolomide, which
offers the advantages of an oral agent with a favorable
toxicity profile compared with procarbazine, lomustine, and
vincristine (PCV); crosses the blood–brain barrier well; and
is more active against glioblastoma than PCV. Phase 2
clinical trials indicate that temozolomide, given on either a
standard 5-day schedule or a dose-dense, metronomic
schedule (3 weeks on, 1 week off or 7 weeks on, 4 weeks
off), is active against both previously irradiated and
unirradiated growing LGGs [29, 46, 47]. Moreover,
228 Curr Neurol Neurosci Rep (2010) 10:224–231temozolomide is associated with a favorable quality-of-life
profile [48].
The two major questions relating to temozolomide use in
LGG are whether temozolomide can substitute for radiation
therapy and whether there is benefit from combining these
two therapeutic modalities. Clinical trials addressing both
these questions have been launched. European and Canadian
investigators initiated a phase 3 clinical trial randomly
assigning patients with LGG to receive either standard
radiation or temozolomide. Patients are stratified based on
chromosome 1p status. PFS is the primary end point, and the
study incorporates neurocognitive and quality-of-life end
points to assess the impacts of radiation and temozolomide
in these regards.
Clinical trials are evaluating the combination of temo-
zolomide with radiotherapy in high-risk LGGs previously
untreated with radiation or chemotherapy. The Radiation
Therapy Oncology Group (RTOG) recently completed
accrual to a phase 2 clinical trial (RTOG 0424) of this
combination; results are not expected before 2013. Under
the aegis of the Eastern Cooperative Oncology Group
(ECOG), the three major US brain tumor cooperative
groups have launched a phase 3 effort (ECOG E3F05)
randomly assigning LGG patients to receive standard
radiation therapy combined with temozolomide and fol-
lowed by a year of temozolomide or to receive radiation
therapy alone. The trial design closely parallels the
European trial of radiation versus temozolomide; in concert,
these two trials should comprehensively address the role of
temozolomide in the management of LGG.
The activity of chemotherapy in recurrent LGG post
radiotherapy, as well as a growing appreciation for the
chemosensitivity of tumors with an oligodendroglial com-
ponent, led the RTOG to study the combination of PCVand
radiation therapy. In this trial (RTOG 9802), patients with
LGG deemed high risk because of age greater than 40 years
or less than GTR were randomly assigned to receive
standard radiation therapy with or without PCV. Although
the cohort receiving chemoradiation had improved PFS, OS
did not differ significantly between the two groups [49],
suggesting that PCV was as active as salvage therapy as in
combination with radiation.
Finally, reports suggest there may be a role for neo-
adjuvant therapy before surgical resection [50]. In both
Suspected
low-grade glioma
History and examination
Diagnostic MRI
LGG confirmed
Low risk High risk
If presumed low risk and
asymptomatic or seizures
are controlled
Observation
Radiation or
temozolomidea
Near or within
eloquent cortices
Not near
eloquent cortices
Not a surgical candidate
due to size or infiltration
Surgical resection with
intraoperative mapping
Standard
surgical resection Biopsy
Preoperative
mapping with fMRI
Seizures
Antiepileptics
Fig. 1 Management of low-
grade glioma (LGG). This flow
diagram outlines a standard
scheme for managing LGG,
emphasizing the need to evalu-
ate patients for surgical resection
as one of the first steps in the
comprehensive, multidisciplin-
ary management of these
tumors. This algorithm necessi-
tates tissue acquisition for man-
agement in most cases, except
for patients who are low risk and
those who are asymptomatic.
Once LGG has been confirmed,
management varies depending
on risk stratification of the pa-
tient, as described in Table 1.I t
is noteworthy that radiation
therapy is delayed until the time
of progression.
aTemozolomide
should be considered for treat-
ment of high-risk patients when
there is evidence of codeletion
of 1p/19q or in the setting of a
clinical trial
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corpus callosum originally prohibited GTR, chemotherapy
shrunk the tumors to the extent that GTR was possible. The
impact of timing of surgery can and will be appreciated
only when a prospective trial is performed, such as was
done for the timing of radiation therapy for the management
of LGG [42].
Conclusions
The management of LGG is changing. New treatment
strategies are being proposed that recognize the potential
risks of a “wait-and-see” policy and radiotherapy as well as
the potential benefits of extensive surgical resection and
upfront chemotherapy. Considering the evidence currently
available, the optimal treatment strategy likely includes
offering extensive surgical resection when possible and
delaying radiotherapy until the time of progression (Fig. 1).
Several trials currently under way almost surely will
revolutionize the treatment of these tumors further, defining
the role of temozolomide in the management of these
tumors and perhaps obviating the need for radiotherapy.
Further multivariate investigations are necessary to define
the prognostic significance of data from novel imaging
techniques and molecular markers of pathogenesis.
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